Introduction

What is the survey about?

Artificial Intelligence (AI), together with big data, has the potential to transform care delivery, and change several aspects of the healthcare value chain: population health, healthcare operations and healthcare-related innovation. Reports and studies also highlight a number of key areas where AI may possibly have a direct impact on the patient: self-care, prevention and wellness, triage and early diagnosis, diagnostics, clinical decision. AI is also a key element of the recently released EU strategy for digital transformation 'Shaping Europe's digital future' and in particular of the EU White Paper on AI (February 2020) and the related public consultation, to which EPF responded in June 2020.

Given this rapid increase of interest in the importance of AI in healthcare and in view of upcoming policy activities, EPF has decided to reinforce its engagement on this matter to ensure that the patients' views will be adequately represented in the future discussion and EU-level debates, starting with this first EPF survey on AI.

Who is the survey for?

The survey includes one single core set of questions, addressed to both individual patients with chronic or long-term conditions, their family members or informal carers and patients' communities, and patients' organisations. You do not need in-depth knowledge on AI in healthcare to complete this survey, questions are primarily about your experience and perception, there are no wrong or right answers. However, to discover more about the topic and about EPF's recent views on it, we invite you to consult the recent EPF publications on AI (see section 'Background Documents').

How will the survey responses be used?

With the results of this survey, EPF intends to produce a report that will serve as additional evidence base for our policy and advocacy work and make recommendations towards EU institutions' policymakers, which we hope will ultimately inform the decisions that are taken at EU and national level.

Immediately, the results will be used to inform EPF's ad-hoc engagement activities on the topic of AI, including for example participation in events or informal exchanges with policymakers and stakeholders.

The survey report will be published and available for free on EPF website in the coming months.

How much time will it take?

This survey consists of around 15 questions, some of which have tick-box options. It should take around 10 - 15 minutes to complete. In our analysis we can only take into consideration completed surveys in order to have reliable and comparable results.

What is the deadline for completing the survey?

The survey is open until 25 October 2020.

Will my identity be published?

The survey is anonymous and the results will be treated as strictly confidential. We only ask for information necessary to analysing the results, e.g., demographic and country information. No personal information will be published. By completing and submitting this survey, as a participant, you are providing your informed consent.

Background documents
Thank you for your interest and for filling out our survey. Below you will find a series of key background documents to help you in your feedback. Clicking on the links below, you will be able to retrieve:
EPF EU Policy Briefing on Big Data and Artificial Intelligence: in this document you can find an overview on current and future state of play on data and AI, including challenges, opportunities and the latest updates from policy at EU level (published in May 2020). For a brief overview on AI, please consult pages 8 - 13.
© <u>EPF Response - Public consultation on the White Paper on AI</u> : in this document you can find our statement in response to the Public consultation on the European White Paper on Artificial Intelligence.
University session explored the impact of Artificial Intelligence meets the health sector: This European Commission's CONNECT University session explored the impact of Artificial Intelligence on the future of healthcare, presenting the major role that AI has in diagnosing and preventing diseases. Ethical issues in the application of AI to healthcare were also included in the discussion.
© <u>EPF Response - Public consultation on the European strategy on data</u> : in this document you can find our statement in response to the Public consultation on the European strategy on data.
For further details, more information about AI in healthcare and any kind of support needed to fill this survey, please do not hesitate to contact michele.calabro@eu-patient.eu

General information about you	
* 1. I am responding on behalf of a:	
Patient organisation	
Individual patient/carer	

ıes	stionnaire for Patient Organisations
1. '	What is the geographical remit of your organisation?
\bigcirc	European
\bigcirc) National
	Regional
\bigcirc) Local
\bigcirc	Open question: if regional or local, please state location.
	Your organisation is based in:
3.	What disease area(s) does your organisation cover? cardiovascular
3.	What disease area(s) does your organisation cover?
3.	What disease area(s) does your organisation cover? cardiovascular
3.	What disease area(s) does your organisation cover? cardiovascular neurological
3.	What disease area(s) does your organisation cover? cardiovascular neurological respiratory
3. '	What disease area(s) does your organisation cover? cardiovascular neurological respiratory metabolic
3. \	What disease area(s) does your organisation cover? cardiovascular neurological respiratory metabolic cancers neuromuscular
3. \	What disease area(s) does your organisation cover? cardiovascular neurological respiratory metabolic cancers neuromuscular rare autoimmune
3.	What disease area(s) does your organisation cover? cardiovascular neurological respiratory metabolic cancers neuromuscular rare autoimmune mental health
3.	What disease area(s) does your organisation cover? cardiovascular neurological respiratory metabolic cancers neuromuscular rare autoimmune


Knowledge about AI implications in healthcare and use of AI-based services or applications
In this section, EPF would like to collect information about both your level of knowledge about AI and its implications in healthcare and, if applicable, about your experience with AI-based services or applications.
If you want to have more information about AI in healthcare before responding to this survey, please have a look at our 'background documents', listed in our introduction page.
* 4. As a patient organisation representative, how would you rate your members' knowledge about Artificial Intelligence and its application in the healthcare field?
They have never heard of AI
They have heard of AI but I they not know how it could apply in healthcare
They have a very basic knowledge of possible AI applications in healthcare
They have a good knowledge of possible AI applications in healthcare, including possible risks, challenges and opportunities, but no technical understanding on how it works.
They have a solid knowledge of possible AI applications in healthcare, including possible risks, challenges and opportunities, and sufficient technical understanding on how it works.
Not applicable/prefer not to answer
* 5. To your knowledge, how would you rate the use of AI-based services or applications among the patient community you represent?
Our community do not use Al-based services or applications
Our community seldomly use Al-based services or applications
Our community regularly use AI-based services or applications
Not applicable/prefer not to answer/I am not sure
Please elaborate on your answer (e.g.If yes, what kind of Al-based services or applications?)
Challenges and opportunities
In this section, EPF would like to collect your views on challenges and opportunities of using AI in health.

	Improve the accuracy of diagnosis
	Improve quality and efficiency of research and innovation in healthcare (e.g. better products)
	Support healthcare professionals in delivering more personalised care to patients
	Facilitate access to care (e.g. Al supported hospital management systems)
	Improve and facilitate self-care or adherence to treatments
	Facilitate better prevention and improve people's well-being
	Better prediction of public health threats (e.g. emerging pandemics)
	Support health systems efficiency and improve organisation and delivery of care
	Provide information and support to patients and carers (e.g. through chat bots)
	Not applicable/prefer not to answer
	Other (please elaborate in the text box below)
CICIC	ences to surveys, papers or documents)
cond	s a patient organisation representative, what are your organisation/patient community main worries cerning the development of AI solutions? You can select up to 3 answers from the list below. Unauthorised use of or access to the data used to train a machine learning model
cond	cerning the development of AI solutions? You can select up to 3 answers from the list below.
cond	cerning the development of AI solutions? You can select up to 3 answers from the list below. Unauthorised use of or access to the data used to train a machine learning model
cond	cerning the development of AI solutions? You can select up to 3 answers from the list below. Unauthorised use of or access to the data used to train a machine learning model Concerns over the quality of the data used to train a machine learning model (e.g. biased or insufficient data)
cond	Cerning the development of AI solutions? You can select up to 3 answers from the list below. Unauthorised use of or access to the data used to train a machine learning model Concerns over the quality of the data used to train a machine learning model (e.g. biased or insufficient data) Lack of transparency on how algorithms are made and work
cond	cerning the development of AI solutions? You can select up to 3 answers from the list below. Unauthorised use of or access to the data used to train a machine learning model Concerns over the quality of the data used to train a machine learning model (e.g. biased or insufficient data) Lack of transparency on how algorithms are made and work Lack of collaboration with healthcare professionals and patients in the co-design of AI solutions
CONC	cerning the development of AI solutions? You can select up to 3 answers from the list below. Unauthorised use of or access to the data used to train a machine learning model Concerns over the quality of the data used to train a machine learning model (e.g. biased or insufficient data) Lack of transparency on how algorithms are made and work Lack of collaboration with healthcare professionals and patients in the co-design of AI solutions Not applicable/prefer not to answer Other (please elaborate in the text box below)
CONC	cerning the development of AI solutions? You can select up to 3 answers from the list below. Unauthorised use of or access to the data used to train a machine learning model Concerns over the quality of the data used to train a machine learning model (e.g. biased or insufficient data) Lack of transparency on how algorithms are made and work Lack of collaboration with healthcare professionals and patients in the co-design of AI solutions Not applicable/prefer not to answer Other (please elaborate in the text box below) se elaborate on your answer(s) (e.g. providing examples or data specific to your disease area or local context adding, if desired
CONC	cerning the development of AI solutions? You can select up to 3 answers from the list below. Unauthorised use of or access to the data used to train a machine learning model Concerns over the quality of the data used to train a machine learning model (e.g. biased or insufficient data) Lack of transparency on how algorithms are made and work Lack of collaboration with healthcare professionals and patients in the co-design of AI solutions Not applicable/prefer not to answer Other (please elaborate in the text box below) se elaborate on your answer(s) (e.g. providing examples or data specific to your disease area or local context adding, if desired
CONC	cerning the development of AI solutions? You can select up to 3 answers from the list below. Unauthorised use of or access to the data used to train a machine learning model Concerns over the quality of the data used to train a machine learning model (e.g. biased or insufficient data) Lack of transparency on how algorithms are made and work Lack of collaboration with healthcare professionals and patients in the co-design of AI solutions Not applicable/prefer not to answer Other (please elaborate in the text box below) se elaborate on your answer(s) (e.g. providing examples or data specific to your disease area or local context adding, if desired

* 8. As a patient organisation representative, what are your organisation/patient community main worries
concerning AI application in healthcare? You can select up to 3 answers from the list below.
Less human interactions with healthcare professionals
Potential risks of overdiagnosis
Potential risks of incorrect diagnosis
Unauthorised use of or access to AI outputs with potential impact on patients' lives (e.g. health insurance)
Limited clarity on liability (e.g. who should respond in case of AI errors?)
Barrier-free access to all AI applications in healthcare and barrier-free access to the underlying data and decisions - in particular in the patient health records
Not applicable/prefer not to answer
Other (please elaborate in the text box below)
Please elaborate on your answer(s) (e.g. providing examples or data specific to your disease area or local context adding, if desired, references to surveys, papers or documents)
Frust and regulations
n this section EPF would like to collect information about current level of trust in AI application in healthcare and knowledge on AI egulations

	s a patient organisation representative, how much would you rate your members' trust Al-based or ported healthcare services or tools?
	Extremely low
	Generally low, but depends on the nature of the decision that AI was being used for (e.g. use of AI for diagnosis or use of AI to better interpret public health statistics)
\bigcirc	Generally sufficient, but depends on the nature of the decision that AI was being used for
	Sufficient, but only if clearly suggested by healthcare professionals
	Very high
	Not applicable/prefer not to answer
trustv	u want, please elaborate on your answer (e.g. What kind of AI use would you be incline to trust more and which one would be less worthy? Why do you trust/not trust AI in healthcare? What would improve your level of trust? Do you think that current AI regulation de enough protection to patients)
10. '	Would you be able to identify who regulates AI in healthcare in Europe?
	The European Union
	Individual member states
	Industry
	Industry A combination of the options above
0	
0	A combination of the options above
	A combination of the options above There is no active AI regulation in Europe Not applicable/prefer not to answer
	A combination of the options above There is no active AI regulation in Europe
	A combination of the options above There is no active AI regulation in Europe Not applicable/prefer not to answer
	A combination of the options above There is no active AI regulation in Europe Not applicable/prefer not to answer
	A combination of the options above There is no active AI regulation in Europe Not applicable/prefer not to answer
If you	A combination of the options above There is no active AI regulation in Europe Not applicable/prefer not to answer u wish, please elaborate on your answer(s)
If you	A combination of the options above There is no active AI regulation in Europe Not applicable/prefer not to answer

	ganisation representative, what kind of knowledge would you/your membership need to Al in healthcare. You can select up to 3 answers from the list below.
Knowing about its	potential risks
Knowing about the	e AI regulations
Basic knowledge	on how AI works in healthcare
Knowing your righ	ts in case of errors (e.g. overdiagnosis or incorrect diagnosis) and how to exercise them
Knowing your righ	ts in case of unauthorised use of or access to the data used to train a machine learning model or Al outputs
Knowing how algo	rithms are made and what data is used to train them?
Knowing how the	Al outputs are used
Barrier-free acces	s to knowledge about Al
Not applicable/pre	fer not to answer
Other (please elab	porate below)
If you wish or your sele	cted 'Other', please elaborate on your answer
-	ur organisation disease area and/or geographical context please feel free to share with s you may have on the application of AI, including challenges or potential interesting
	share with us any relevant project or current AI applications that you may be aware of, sible, the impact on patients. Please provide references/links to websites or documents.
• •	ner be contacted further, for example for an interview, or if you agree to be quoted, t details (name of your organisation and email address) below
Name of your organisation	
Email address	



	stionnaire for individual patients and communities		
1. A	Are you:		
	A patient with chronic or long term condition(s)		
	A parent/family member/informal carer		
\bigcirc	A patient and informal carer		
2. Y	Your country of residence is:		
3. V	What age group are you? (or the patient you are respond	ng on behalf of)	
\bigcirc	0-15		
\bigcirc	16-30		
\bigcirc	31-45		
\bigcirc	46-60		
\bigcirc) 61-75		
\bigcirc	76 and above		
4. V	What is your gender?		
\bigcirc) Male		
\bigcirc) Female		
\bigcirc	Other		
\bigcirc	Prefer not to say		

neu res me car neu rare aut	rdiovascular urological spiratory etabolic ncers uromuscular re ental health toimmune
res me car neu me aut	spiratory etabolic ncers uromuscular re
me car neu	etabolic ncers uromuscular re
car neu rare aut	ncers uromuscular ee ental health
neu rare me aut	uromuscular re ental health
rare me	ental health
me aut	ental health
aut	
	toimmune
Oth	
	her (please specify)
his sectic licable, a	e about AI implications in healthcare and use of AI-based services or applications on, EPF would like to collect information about both your level of knowledge about AI and its implications in healthcare and, if about your experience with AI-based services or applications. to have more information about AI in healthcare before responding to this survey, please have a look at our 'background
6. How	, listed in our introduction page v would you rate your knowledge about Artificial Intelligence and its application in the healthcare field? ever heard of AI
O I ha	ave heard of AI but I do not know how it could apply in healthcare
☐ I ha	ave a very basic knowledge of possible AI applications in healthcare
	ave a good knowledge of possible AI applications in healthcare, including possible risks, challenges and opportunities, but no chnical understanding on how it works.
☐ I ha	ave a solid knowledge of possible AI applications in healthcare, including possible risks, challenges and opportunities, and fficient technical understanding on how it works.

No No I am not sure Not applicable/prefer not to answer Please elaborate on your answer (e.g.lf yes, what kind of Al-based services or applications?) Challenges and opportunities	
Not applicable/prefer not to answer Please elaborate on your answer (e.g.lf yes, what kind of Al-based services or applications?)	
Not applicable/prefer not to answer Please elaborate on your answer (e.g.If yes, what kind of Al-based services or applications?)	
Please elaborate on your answer (e.g.If yes, what kind of Al-based services or applications?)	
hallenges and opportunities	
hallenges and opportunities	
nallenges and opportunities	
nallenges and opportunities	
nallenges and opportunities	
this section, EPF would like to collect your views on challenges and opportunities of using AI in health.	
* 8. In your opinion, what are the most interesting positive aspects of using AI in health? You can sele	act up to 1
answers from the list below.	set up to s
Improve the accuracy of diagnosis	
Improve quality and efficiency of research and innovation in healthcare (e.g. better products)	
Support healthcare professionals in delivering more personalised care to patients	
Facilitate access to care (e.g. Al supported hospital management systems)	
Improve and facilitate self-care or adherence to treatments	
Facilitate better prevention and improve people's well-being	
Better prediction of public health threats (e.g. emerging pandemics)	
Support health systems efficiency and improve organisation and delivery of care	
Provide information and support to patients and carers (e.g. through chat bots)	
Not applicable/prefer not to answer	
Other (please elaborate in the text box below)	
Please elaborate on your answer(s) (e.g. providing examples or data specific to your disease area or local context adding,	if desired,
references to surveys, papers or documents)	

	n the list below.
	Unauthorised use of or access to the data used to train a machine learning model
	Concerns over the quality of the data used to train a machine learning model (e.g. biased or insufficient data)
	Lack of transparency on how algorithms are made and work
	Lack of collaboration with healthcare professionals and patients in the co-design of Al solutions
	Not applicable/prefer not to answer
	Other (please elaborate in the text box below)
	se elaborate on your answer(s) (e.g. providing examples or data specific to your disease area or local context adding, if desired, ences to surveys, papers or documents)
	What are your main worries concerning AI applications in healthcare? You can select up to 3 answers filist below.
	Less human interactions with healthcare professionals
	Potential risks of overdiagnosis
	Potential risks of incorrect diagnosis
	Unauthorised use of or access to AI outputs with potential impact on patients' lives (e.g. health insurance)
	Limited clarity on liability (e.g. who should respond in case of AI errors?)
	Barrier-free access to all AI applications in healthcare and barrier-free access to the underlying data and decisions - in particular the patient health records
	Not applicable/prefer not to answer
	Other (please elaborate in the text box below)
	se elaborate on your answer(s) (e.g. providing examples or data specific to your disease area or local context adding, if desired ences to surveys, papers or documents)
	d regulations
st an	

Not at all
Generally no, but depends on the nature of the decision that AI was being used for (e.g. use of AI for diagnosis or use of AI to bette interpret public health statistics)
Generally yes, but depends on the nature of the decision that AI was being used for
Only if clearly suggested by my doctor
Entirely
Not applicable/prefer not to answer
If you want, please elaborate on your answer (e.g. What kind of AI use would you be incline to trust more and which one would be less trustworthy? Why do you trust/not trust AI in healthcare? What would improve your level of trust? Do you think that current AI regulations provide enough protection to patients)
* 12. Would you be able to identify who regulates AI in healthcare in Europe?
* 12. Would you be able to identify who regulates AI in healthcare in Europe? The European Union
 Individual member states
Industry
A combination of the options above
There is no active AI regulation in Europe
Not applicable/prefer not to answer
If you wish, please elaborate on your answer(s)
Iditional questions
this section, EPF would like to collect any additional views and experiences about AI in healthcare, including desired knowledge on stopic but also prospective AI challenges, active projects, studies or interesting applications.
s topic but also prospective in chancinges, active projects, stadies of interesting applications.

alls	wers from the list below.							
	Knowing about its potential risks							
	Knowing about the AI regulations							
	Basic knowledge on how AI works in healthcare							
	Knowing your rights in case of errors (e.g. overdiagnosis or incorrect diagnosis) and how to exercise them Knowing your rights in case of unauthorised use of or access to the data used to train a machine learning model or Al outputs Knowing how algorithms are made and what data is used to train them?							
	Knowing how the AI outputs are used							
	Barrier-free access to knowledge about Al							
	Not applicable/prefer not to answer							
	Other (please elaborate below)							
If you	u wish or your selected 'Other', please elaborate on your answer							
lditio	th regards to your disease area and/or geographical context please feel free to share with us any nal views you may have on the application of AI, including challenges or potential interesting tions.							
	ase feel free to share with us any relevant project or current AI applications that you may be aware of, ng, where possible, the impact on patients. Please provide references/links to websites or documents.							

	nd email address) bel	clerosis from Der	ımark") piease	provide your co	ontact
Full name					
Email address					

Thank you for co	mpleting our survey!			_
If you have not already	done so, please share this survey v	with your network by using	g this link: <u>https://www.surve</u>	ymonkey.com/r/AIEPF
The deadline to complete	e the survey is 25 October.			
The survey report will be	e published and available for free o	n EPF website in the con	ning months.	
For any questions or qu	eries, please contact: michele.cala	abro@eu-patient.eu		